Dementia Drugs Market Revenue, Size, Share & Opportunity Analysis ReportBy Type (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, and Others), By Drug Class (MAO Inhibitors, Glutamate Inhibitors, and Cholinesterase Inhibitor), By Region, And Segment Forecasts, 2025 – 2032

Dementia Drugs Market Size & Trends

The Global Dementia Drugs Market size was valued at USD 17.98 billion in 2024. The market is projected to grow from USD 19.30 billion in 2025 to USD 31.71 billion by 2032, exhibiting a CAGR of 7.35% during the forecast period.

Market Definition & Introduction

Pharmaceuticals known as dementia medications are used to treat the symptoms of dementia, which is characterised by a progressive decline in cognitive function. These drugs typically target neurotransmitters that are involved in behaviour, memory, and cognition. The dementia medicine sector is impacted by a number of dynamic factors. The market is expanding due to factors like the ageing population, an increase in dementia cases, and increased government support. However, there are significant obstacles such as a lack of therapy options, high drug costs, and difficulties in drug development. In addition, the COVID-19 pandemic changed market dynamics by affecting patient care and rerouting resources. Notwithstanding these drawbacks, the industry may have opportunities due to research advancements and a growing focus on early identification.

In April 2024, The acquisition of Reminyl oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company, has been completed, according to Essential Pharma, an international speciality pharmaceutical group committed to guaranteeing patients' long-term access to low-volume, clinically differentiated, niche pharmaceutical products in important therapeutic areas. A well-known central nervous system (CNS) medication for mild to moderately severe Alzheimer's dementia is called Reminyl, a cholinesterase inhibitor. With the exception of the UK and Ireland, Japan, and Latin America, Essential Pharma now owns the rights to Reminyl oral capsules in the European Economic Area, Thailand, South Korea, and every other current market for the medication.(Source: https://essentialpharmagroup.com/essential-pharma-announces-the-acquisition-on-reminyl-galantamine-hydrobromide-oral-capsules/).

Market Drivers

Growing Dementia Prevalence is Driving the Demand for Dementia Drugs Market.

The market for dementia medications has grown steadily due to the rising incidence of dementia. There is an urgent need for efficient therapeutic strategies because the occurrence of this crippling ailment has increased as the world's population ages. increasing dementia prevalence. Every 20 years, this number is predicted to nearly double, reaching 78 million in 2030 and 139 million in 2050. 60% of dementia patients reside in low- and middle-income nations. Increased demand for medications meant to control symptoms and maybe halt the progression of the disease has resulted from the rise in dementia cases, which has accelerated market expansion.

Market Trend

Population Ageing Increasingly to Boost the Demand in the Forecast Period.

The market for dementia medications has expanded as a result of the ageing population. Age-related neurodegenerative disorders like Parkinson's and Alzheimer's are becoming more common as life expectancy rises. Between 2015 and 2050, the percentage of people in the world who are 60 years of age or older is expected to almost double, from 12% to 22%. Between 2020 and 2050, there will likely be three times as many persons 80 years of age or older. The market is expanding as a result of the substantial and rising demand for therapeutic interventions to control and possibly treat dementia brought about by this demographic transition.

COVID Impact on Dementia Drugs Market

The industry of dementia medications was significantly impacted by the COVID-19 epidemic. On the one hand, the pandemic caused healthcare resources and attention to shift to managing the acute phase of the virus, which may cause delays or disruptions in the diagnosis and treatment of dementia. Additionally, patients found it challenging to regularly manage their medication and obtain healthcare services due to lockdowns and restrictions. On the other hand, the pandemic increased awareness of dementia and its related problems by highlighting the vulnerability of the elderly population. This heightened interest might inspire more research and advancement in the field. The market for dementia medications may be shaped by the ongoing research into the long-term impact of COVID-19 on the course of dementia and the potential for an increase in dementia cases.

Competitive Landscape

A variety of companies are vying for market share in the dementia drugs industry through strong marketing campaigns, strategic alliances, and new product development. Established pharmaceutical manufacturers, specialty dementia medicine businesses, and up-and-coming start-ups hoping to upend the industry with creative solutions are some of the major participants in the market.

Dementia Drugs Companies

Johnson & Johnson

Eli Lilly and Company

Biogen Idec

Eisai Co., Ltd.

Aurobindo Pharma Ltd

Teva Pharmaceutical Industries

AbbVie Inc.

F. Hoffmann-La Roche AG

Company Strategic Developments

In March 2022: The main treatments for dementia brought on by Alzheimer's disease are memantine and donepezil, and a special combination of these two molecules has been developed and patented by NovaMedica, a Russian pharmaceutical company (a RUSNANO investment initiative). The medication is registered under the name MIOREO. The Russian market, as well as the EAEU and European markets, have never seen such a combination before.

In April 2022: The FDA has approved Corium, Inc.'s ADLARITY (donepezil transdermal system) treatment for mild, moderate, or severe Alzheimer's dementia. Corium, Inc. is a commercial-stage biopharmaceutical business that focusses on creating and promoting innovative CNS medicines. The first and only once-weekly patch, ADLARITY, administers consistent doses of donepezil via the skin, lowering the risk of the negative gastrointestinal (GI) side effects that come with oral donepezil. ADLARITY is the first registered prescription medication to use Corium's proprietary CORPLEX transdermal technology, which has long been a feature of consumer goods.

Segment Analysis

Dementia Drugs Market, by Type

The alzheimer’s disease segment is expected to dominate the dementia drugs market. One of the main factors propelling market expansion is the growing emphasis on the study and creation of efficient Alzheimer's treatments. The substantial need for dementia medications is highlighted by the high incidence of Alzheimer's disease, especially in the senior population. For example, according to the Alzheimer's Association, a significant portion of Americans have Alzheimer's, and that number is expected to increase significantly. Even though there have been some improvements, such the FDA approving medications like Aduhelm, the general state of treatment is still difficult. All of these elements work together to support the growing market for dementia medications.

However, the parkinson's disease segment is expected to grow at the fastest CAGR during the forecast period. Although Alzheimer's disease is still the most common type, there has been significant advancement in this field due to the growing understanding that Parkinson's is a neurodegenerative illness that affects cognition. The typical age of onset for Parkinson's disease is around 60, and its incidence rises with age. Nonetheless, a sizable portion of instances involve younger people. Parkinson's disease affects about 10 million individuals worldwide. Parkinson's disease has become a major focus in the dementia medication landscape due to the special difficulties it presents, which include both motor and cognitive symptoms.

Dementia Drugs Market, by Drug Class

The MAO inhibitors segment is expected to dominate the dementia drugs market. In the past, MAO inhibitors were used to treat dementia, especially dementia linked to Parkinson's disease. These medications function by raising levels of critical brain chemicals. But because of serious adverse effects and the emergence of safer, more modern therapy alternatives, their use has decreased. MAO inhibitors are no longer regarded as the main treatment for dementia, though they may still play a small part in certain situations.

However, the glutamate inhibitors segment is expected to grow at the fastest CAGR during the forecast period. These medications work to prevent harm to brain cells by preventing glutamate, a crucial neurotransmitter, from acting excessively. The potential advantages of glutamate inhibitors in reducing the progression of disease and enhancing patients' lives have made this therapy class a primary target for pharmaceutical companies, even if research is still ongoing.

Regional Analysis

According to InfoNest Market Analytics, the North American dementia drugs market held a share of 37.59% in 2024. The market has grown as a result of the region's robust healthcare system and early diagnosis initiatives. The market for dementia medications is thriving because of North America's dedication to investing in healthcare, including medication development and patient care.

The Asia Pacific dementia drugs market is expected to register the fastest CAGR of 8.16% during the forecast period of 2025-2032. There are numerous growth opportunities for dementia drug companies in important markets such as Singapore, Japan, China, India, and Australia. The primary drivers driving the growth of the dementia drugs market in this region are expanding government initiatives, rising demand for fast computing, virtualised environments, analytics, security, digitalisation, high-volume networking, and enhanced overall internet speed and responsiveness.

Segmentation

Type Outlook (Revenue, USD Million, 2019-2032)

Drug Class Outlook (Revenue, USD Million, 2019-2032)

The Report Covers